Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent Relating to NTx®-265
News Dec 09, 2010
The claims cover the use of luteinizing hormone (LH) or human chorionic gonadotrophin (hCG) and erythropotein (EPO) for producing neural stem cells (in vitro & in vivo), which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The covered in vivo uses include administration of these compounds to subjects having neurodegenerative conditions, diseases and CNS injuries. This is the first U.S. patent to issue in this patent family and it protects the use of the NTx(R)-265 regimen in the acute neurologic injury indications of Stroke, and Traumatic Brain Injury, amongst other indications.
Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as follows:
"We at SCT are very excited to see this patent issue as it represents an important intellectual property milestone for the NTx(R)-265 program. This patent offers protection and support for our NTx(R)-265 technology, a keystone patent, while expanding and increasing value to SCT's overall intellectual property portfolio."
A human pluripotent stem cell line has been engineered which contains two ‘suicide genes’ that induce cell death in all but the desired insulin-producing cells. This double fail-safe approach opens the door to creating safe cell-replacement therapies for people living with type 1 diabetes.READ MORE